Author

C. Leath

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib.

BACKGROUND Pembrolizumab, a PD-1 immune checkpoint inhibitor, has shown promise in various cancers, but its role in ovarian cancer remains under investigation. While the current standard of care (SOC) is initially effective for epithelial ovarian cancer (EOC), approximately 70% of patients relapse within 3 years of com...

Carson C. Edwards, Kati A. Turner, Kaitlyn G. Dinkins et al. · Gynecologic Oncology · 0 citations

Clinical trial Oct 2026

Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with various solid tumors with FGFR1 or FGFR2 alterations treated with sunitinib are reported. METHODS Eligi...

Gordan Srkalovic, M. Rothe, E. Garrett-Mayer et al. · JCO Precision Oncology · 0 citations

Aug 2026

Trends in U.S. Gynecologic Cancers (2001-2019): Influence of Social Determinants, Geographic Disparities, and Specialist Access on Stage at Diagnosis.

Disparities in gynecologic cancer stage at diagnosis are driven by race/ethnicity, social vulnerability, and poor geographic access to specialty care, and targeted strategies are needed to reduce late-stage diagnosis and improve outcomes in marginalized communities.

Michael R. Desjardins, N. Desravines, Visha Patel et al. · American Journal of Obstetri... · 0 citations